Literature DB >> 6166817

Midodrine. A new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome.

A Schirger, S G Sheps, J E Thomas, R D Fealey.   

Abstract

Five patients with idiopathic orthostatic hypotension, two of whom had central nervous system manifestations (Shy-Drager syndrome), were treated with midodrine, an investigational alpha-adrenergic agonist, in a dosage of 2.5 to 5 mg three times daily. Significant improvement was observed in the standing systolic and diastolic blood pressures at the end of 1 week of therapy in all patients and has been maintained for 10 to 15 months in all patients. No symptomatic side effects were noted. Supine systolic hypertension occurred in two patients and was treated with small doses of metoprolol.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166817

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  14 in total

1.  Autonomic dysfunction: diagnosis guided by therapy.

Authors:  R M Robertson; I Biaggioni; R Mosqueda-Garcia; D Robertson
Journal:  Trans Am Clin Climatol Assoc       Date:  1992

Review 2.  Management of neurogenic orthostatic hypotension in patients with autonomic failure.

Authors:  Christoph Schroeder; Jens Jordan; Horacio Kaufmann
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

3.  Midodrine for TCA-induced orthostatic hypotension.

Authors:  D D Maskall; R W Lam
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

4.  Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges.

Authors:  Jose-Alberto Palma; Horacio Kaufmann
Journal:  Semin Neurol       Date:  2020-09-09       Impact factor: 3.420

5.  Idiopathic orthostatic hypotension, midodrine, and anaesthesia.

Authors:  P J Osborne; L W Lee
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

6.  Failure of erythropoietin treatment in a case with primary autonomic failure.

Authors:  L Keselbrener; A Korzets; S Akselrod
Journal:  Clin Auton Res       Date:  1997-12       Impact factor: 4.435

Review 7.  Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology.

Authors:  J F Cubells; C P Zabetian
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

8.  Pretransplant Midodrine Use: A Newly Identified Risk Marker for Complications After Kidney Transplantation.

Authors:  Tarek Alhamad; Daniel C Brennan; Zaid Brifkani; Huiling Xiao; Mark A Schnitzler; Vikas R Dharnidharka; David Axelrod; Dorry L Segev; Krista L Lentine
Journal:  Transplantation       Date:  2016-05       Impact factor: 4.939

9.  The head and neck discomfort of autonomic failure: an unrecognized aetiology of headache.

Authors:  D Robertson; D W Kincaid; V Haile; R M Robertson
Journal:  Clin Auton Res       Date:  1994-06       Impact factor: 4.435

10.  Observations on midodrine in a case of vasodepressor neurogenic syncope.

Authors:  C Ward; R A Kenny
Journal:  Clin Auton Res       Date:  1995-10       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.